MedPath

Nitazoxanide

Generic Name
Nitazoxanide
Brand Names
Alinia, Busulfex
Drug Type
Small Molecule
Chemical Formula
C12H9N3O5S
CAS Number
55981-09-4
Unique Ingredient Identifier
SOA12P041N
Background

Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .

Indication

用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。

Associated Conditions
Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts

Phase 4
Conditions
SARS-CoV-2 Infection
Covid19
Households Contacts
Interventions
Drug: Placebo
Drug: Nitazoxanide
First Posted Date
2021-03-09
Last Posted Date
2021-07-02
Lead Sponsor
Fundación Huésped
Target Recruit Count
456
Registration Number
NCT04788407
Locations
🇦🇷

Fundación Huésped., Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina

Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis

Phase 3
Conditions
Spontaneous Bacterial Peritonitis
Interventions
Drug: Nitazoxanide
Drug: Norfloxacin
First Posted Date
2021-02-10
Last Posted Date
2021-02-10
Lead Sponsor
Tanta University
Target Recruit Count
60
Registration Number
NCT04746937

AGILE (Early Phase Platform Trial for COVID-19)

Phase 1
Active, not recruiting
Conditions
Covid19
Interventions
Drug: Nitazoxanide
Drug: VIR-7832
Drug: VIR-7831
Drug: Favipiravir
Drug: Molnupiravir
Drug: ALG-097558
Drug: NHS standard of care as per COVID-19 treatment guidelines
Drug: Paxlovid
Drug: ALG-097558 and Remdesivir
First Posted Date
2021-02-09
Last Posted Date
2024-11-19
Lead Sponsor
University of Liverpool
Target Recruit Count
600
Registration Number
NCT04746183
Locations
🇬🇧

Manchester University NHS Foundation Trust, Manchester, United Kingdom

🇿🇦

Desmond Tutu Health Foundation, Cape Town, South Africa

🇿🇦

Ezintsha, Johannesburg, South Africa

and more 3 locations

EAT-DUTA AndroCoV Trial

Phase 2
Completed
Conditions
Covid19
Interventions
Drug: Dutasteride 0.5 mg
Drug: Azithromycin
Drug: Placebo
Drug: Nitazoxanide
First Posted Date
2021-01-28
Last Posted Date
2021-01-28
Lead Sponsor
Corpometria Institute
Target Recruit Count
138
Registration Number
NCT04729491
Locations
🇧🇷

Corpometria Institute, Brasília, DF, Brazil

A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

First Posted Date
2020-10-28
Last Posted Date
2022-05-05
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
7
Registration Number
NCT04605588
Locations
🇺🇸

Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

COVID-19 Prophylaxis South Africa (COVER HCW)

Phase 2
Completed
Conditions
SARS-CoV Infection
Covid19
Interventions
Drug: Sofosbuvir/Daclatasvir
Drug: Nitazoxanide
First Posted Date
2020-09-23
Last Posted Date
2022-06-07
Lead Sponsor
University of Witwatersrand, South Africa
Target Recruit Count
1950
Registration Number
NCT04561063
Locations
🇿🇦

Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa

🇿🇦

Sunnyside Office Park, Johannesburg, Gauteng, South Africa

Nitazoxanide Therapy for Patients With COVID-19 Pneumonia

Phase 2
Completed
Conditions
Covid19
Pneumonia, Viral
Corona Virus Infection
Interventions
Drug: Nitazoxanide
Drug: Placebo
First Posted Date
2020-09-23
Last Posted Date
2021-07-22
Lead Sponsor
Universidade Federal do Rio de Janeiro
Target Recruit Count
500
Registration Number
NCT04561219
Locations
🇧🇷

Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil

Effects of Early Use of Nitazoxanide in Patients With COVID-19

Phase 2
Completed
Conditions
Covid19
Coronavirus
Interventions
Drug: Placebo
Drug: Nitazoxanide
First Posted Date
2020-09-17
Last Posted Date
2020-11-03
Lead Sponsor
Universidade Federal do Rio de Janeiro
Target Recruit Count
392
Registration Number
NCT04552483
Locations
🇧🇷

Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil

Catalysing the Containment of COVID-19

Phase 2
Terminated
Conditions
COVID-19
Interventions
Drug: Placebo
Drug: Nitazoxanide
First Posted Date
2020-08-21
Last Posted Date
2022-08-16
Lead Sponsor
University of Cape Town
Target Recruit Count
322
Registration Number
NCT04523090
Locations
🇿🇦

The Aurum Institute, Tembisa, Gauteng, South Africa

🇿🇦

University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa

🇿🇦

Perinatal HIV Research Unit, Klerksdorp, North West, South Africa

and more 1 locations

Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19

Phase 4
Completed
Conditions
COVID
Interventions
Drug: Sofosbuvir and Ledipasvir
Drug: Nitazoxanide
First Posted Date
2020-08-05
Last Posted Date
2020-11-12
Lead Sponsor
Assiut University
Target Recruit Count
240
Registration Number
NCT04498936
Locations
🇪🇬

Assiut University Hospital, Assiut, Egypt

🇪🇬

15th May Hospital, Helwan, Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy